Total raised
$6.3M
Last: Series A 2015-09
Stage
Series A
Founded
2013
Headcount
21
HQ
Petah Tikva
Sector
Health Tech & Life Sciences
About
Coramaze Technologies develops the Tripair, a simple, rapid, and effective percutaneous treatment for tricuspid valve disease. The treatment is intended to improve quality of life and reduce morbidity for heart failure patients suffering from tricuspid regurgitation. The Tripair implant is anchored a-traumatically in the right atrium, enabling full retrievability and intraprocedural efficacy evaluation while reducing regurgitation even in the most severe cases.
Funding history · 2 rounds · $6.3M total
2015-09
Series A
$5.2M
2014-02
Seed
$1.1M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 PatentsVerified
Tags
heart-failurevascularcardiologycathetersminimally-invasiveheart-diseasesmedical-technologiescardiovascularmedical-devices